SAN DIEGO & PHILADELPHIA--(BUSINESS WIRE)--Capstan Therapeutics, Inc., a biotechnology company dedicated to developing and delivering precise in vivo cell engineering to patients, launched today with ...
SAN DIEGO--(BUSINESS WIRE)--Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery utilizing targeted lipid ...
AbbVie announced this morning it would buy clinical-stage biotech company Capstan Therapeutics for up to $2.1 billion in cash, picking up the company's in vivo CAR-T therapy candidate. San Diego-based ...
(Reuters) -AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product pipeline with experimental ...
Capstan Therapeutics — a biotechnology company pioneered by Penn researchers — was acquired by AbbVie in $2.1 billion deal. Capstan, which specializes in CAR-T therapies for autoimmune disorders, ...
(RTTNews) - Biopharmaceutical company AbbVie, Inc. (ABBV) and privately-held clinical-stage biotechnology company Capstan Therapeutics, Inc., announced Monday a definitive agreement under which AbbVie ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A University of Pennsylvania ...
The company offers surgical robotics with catheter-based technology and implants to repair and replace heart valves. It will use the funds to advance its reach within healthcare. "Percutaneous ...
A startup that aims to integrate robotics with minimally invasive heart valve procedures has collected $31.4 million in venture capital funding. While robots have made inroads in many different types ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results